Bioventus Inc. (BVS)

3,9600 -0,1100 (-2,70%) Alla chiusura: 04:00PM EDT

Bioventus Inc.

4721 Emperor Boulevard
Suite 100
Durham, NC 27703
United States
919 474 6700
https://www.bioventus.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 970

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Mark L. Singleton	Senior VP & CFO	740,04k	N/D	1970
Mr. Anthony D'Adamio	Senior VP, General Counsel & Corporate Secretary	705,38k	N/D	1961
Mr. Robert E. Claypoole	President, CEO & Director	N/D	N/D	1972
Mr. Mike Crowe B.S., M.B.A.	Senior Vice President of Operations	N/D	N/D	N/D
Mr. David Crawford	Vice President of Investor Relations & Treasurer	N/D	N/D	N/D
Ms. Katrina J. Church J.D.	Senior VP & Chief Compliance Officer	N/D	N/D	1962
Ms. Helen Leupold	Senior VP & Chief Human Resources Officer	N/D	N/D	N/D
Mr. Larry Chen	Managing Director of China & Asia Pacific	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Governance aziendale

L'ISS Governance QualityScore di Bioventus Inc. al 29 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 6; diritti degli azionisti: 6; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.